Loading clinical trials...
Loading clinical trials...
Effect of Early Prescription of Immunosuppressants on First Three-year Course of Crohn's Disease
Pluricentric randomized study comparing two therapeutic strategies at beginning of Crohn's disease: early immunosuppressants (prescription within the six first months following diagnosis) vs. conventional strategy (immunosuppressants given only in case of steroid failure, in a selected group of patients being at high risk of disabling course. The hypothesis is that immunosuppressants given early may improve the disease course during the 3 following years in this subset of patients.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Chu Amiens
Amiens, France
Chu Besancon
Besançon, France
CHU CAEN
Caen, France
Chu Clermont-Ferrand
Clermont-Ferrand, France
Hopital Beaujon
Clichy, France
Hopital Louis Mourrier
Colombes, France
Hopital Bicetre
Le Kremlin-Bicêtre, France
Chru Lille
Lille, France
Chu Marseille - Hopital Nord
Marseille, France
Ch Le Raincy Montfermeil
Montfermeil, France
Start Date
July 1, 2005
Primary Completion Date
December 1, 2012
Completion Date
June 1, 2013
Last Updated
April 28, 2015
120
ACTUAL participants
early immunosuppressants (azathioprine, methotrexate)
DRUG
Lead Sponsor
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Collaborators
NCT06226883
NCT07184931
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06918808